Applied DNA Sciences: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Applied DNA Sciences (NASDAQ:APDN) reported Q4 earnings with an EPS of $-0.26, slightly beating the estimate of $-0.27. However, revenue decreased by $2.78 million compared to the same period last year. In the previous quarter, a miss on EPS resulted in a 10.86% share price drop the following day. The company's past earnings performance shows variability in meeting EPS estimates and fluctuating revenues.
December 07, 2023 | 9:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
APDN reported a marginal earnings beat in Q4 but saw a significant year-over-year revenue decline. Historical data suggests that past earnings misses have negatively impacted the stock price.
While APDN beat EPS estimates, the revenue decline is substantial and may concern investors, potentially leading to a negative short-term impact on the stock price. Historical performance indicates that earnings misses have previously led to stock price declines, suggesting that the market is sensitive to APDN's earnings reports.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100